Speakers

  • Hanny Al-Samkari, MD

    Dr. Hanny Al-Samkari is the Peggy S. Blitz Endowed Chair in Hematology/Oncology at the Massachusetts General Hospital and an Associate Professor of Medicine at Harvard Medical School. He is a classical hematologist and NIH-funded clinical investigator and clinical trialist. He also serves as Co-Director the MGH Hereditary Hemorrhagic Telangiectasia (HHT) Center of Excellence. His clinical and research interests are in hemostasis, thrombosis and hemolysis, with focuses in HHT, thrombocytopenias, and hemolytic anemias. As a clinical investigator, Dr. Al-Samkari is an internationally recognized expert in the clinical development of novel therapeutics for these disorders and serves as the lead principal investigator for multiple ongoing clinical trials. He is a current Associate Editor of the American Journal of Hematology and the Journal of Thrombosis and Haemostasis. He has published over 200 peer-reviewed manuscripts. His original research has been featured in The New England Journal of Medicine, The Lancet, Annals of Internal Medicine and Blood, among other top peer-reviewed journals in hematology and medicine.

  • Jennifer R. Brown, MD, PhD

    Jennifer R. Brown, M.D., Ph.D. is the Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute (DFCI) and the Worthington and Margaret Collette Professor of Medicine in the Field of Hematologic Oncology at Harvard Medical School in Boston, Massachusetts. She has been instrumental in the clinical development of idelalisib, ibrutinib, zanubrutinib and acalabrutinib-venetoclax, leading to their regulatory approvals in CLL. Her genomics work has characterized the somatic mutation profile of CLL, and she also has a longstanding research interest in the inherited predisposition to CLL. To date, she has published about 335 papers in the scientific literature, predominantly in CLL. She is a member of the International Workshop on CLL (iwCLL) and enjoys a worldwide reputation as a CLL expert having made the Highly Cited Researchers list by Clarivate, with multiple papers ranking in the top 1% by citations for their field and year of publication.

  • Adam Cuker, MD, MS

    Adam Cuker, M.D., M.S, is Professor of Medicine and Professor of Pathology & Laboratory Medicine at the University of Pennsylvania. He is Chief of the Section of Hematology, Director of the Penn Comprehensive Hemophilia & Thrombosis Program, and Assistant Director of the Penn Specialized Coagulation Laboratory. He is a Councilor on the American Society of Hematology (ASH) Executive Committee and a member of the Board of Directors of the Hemostasis and Thrombosis Research Society. He conducts patient-oriented research on disorders of hemostasis and thrombosis.

  • Amy DeZern, MD, MHS

    Amy E. DeZern, MD, MHS, is Professor of Oncology and Vice Chair for Hematologic Malignancies at the Johns Hopkins University School of Medicine. She directs the Bone Marrow Failure and Myelodysplastic Syndromes Program at the Sidney Kimmel Comprehensive Cancer Center. Dr. DeZern is an internationally recognized physician-scientist and clinical trialist whose work focuses on bone marrow failure syndromes, myelodysplastic syndromes, acute myeloid leukemia, hematopoietic cell transplantation, and the translation of novel therapies into clinical practice. After earning her medical degree from the Johns Hopkins University School of Medicine, she completed residency training through the Osler Medical Service, fellowships in Medical Oncology and Hematology at Johns Hopkins, and a Master of Health Science in Clinical Investigation from the Johns Hopkins Bloomberg School of Public Health. She has served as principal investigator for more than 40 clinical trials and has built nationally recognized clinical and research programs in bone marrow failure and myeloid malignancies. As Vice Chair, she has helped lead the growth of the Johns Hopkins Hematologic Malignancies, Bone Marrow Transplantation, and Cellular Therapy enterprise.

  • James Douketis, MD, FRCP(C), FCAHS

    Dr. Douketis is a Staff Physician in General Internal Medicine and Thromboembolism at St. Joseph’s Healthcare Hamilton. He is Professor of Medicine and holds the David Braley-Nancy Gordon Chair in Thromboembolic Disease at McMaster University.

    Training: He received his M.D. and did internal medicine at the University of Toronto, followed by a thrombosis fellowship at McMaster University.

    Research: Includes perioperative anticoagulant management and related guideline development, and the prevention, treatment and prognosis of patients with venous thromboembolism. He has 480 peer-reviewed publications with an h-index=113, i-index=365, and ~117K citations (June 2026).

    Leadership: He holds leadership positions in national and international thrombosis societies, and has editorial roles in multiple thrombosis/internal medicine journals.

    Social: Jim lives in Hamilton, Canada with his wife, Dr. Margaret Nowaczyk, a clinical geneticist, has two sons, Jack and Luke, and is a cellist with the Burlington Symphony Orchestra.

  • Andrew Evens, DO, MBA, MSc

    Andrew M. Evens, DO, MBA, MSc, is SVP & Chief Medical Officer of RWJBarnabas Medical Group & RWJ BarnabasHealth. He serves as Deputy Director for Clinical Services and Chief Physician Officer at the Rutgers Cancer Institute and the Jack & Sheryl Morris Cancer Center, and Associate Vice Chancellor for Clinical Innovation and Data Analytics at Rutgers Health. He also serves as Professor of Medicine for Rutgers Robert Wood Johnson Medical School. He oversees integrated cancer care across 16 acute care hospitals and more than 40 ambulatory oncology practices in New Jersey. An internationally recognized expert in lymphoid malignancies, Dr. Evens’ research focuses on novel therapeutics, predictive modeling, and personalized medicine. He has maintained continuous NIH and NCI funding since 2005, served as principal investigator on more than 80 prospective clinical trials, and authored over 250 peer reviewed publications. He is Editor in Chief of the British Journal of Haematology and holds multiple national leadership roles in lymphoma research.

  • Brad Kahl, MD

    Dr. Kahl’s is a Professor of Medicine at Washington University in St. Louis and Director of the Lymphoma Program at the Siteman Cancer Center. His clinical interests involve the care of patients with Hodgkin lymphoma, non-Hodgkin’s lymphoma, and chronic lymphocytic leukemia. His research focuses on the development of new treatments for lymphoma patients, with emphasis on novel agents. He is the Chairman of the ECOG-ACRIN Lymphoma Committee, an NCI funded national cancer research group which is dedicated to advancing lymphoma research, with a focus on improving patient outcomes and developing innovative treatments for various types of lymphoma.

  • Ruben Mesa, MD

    Dr. Ruben Mesa is senior vice president of Advocate Health and the president of the Advocate Health Cancer National Service Line (and executive director of the National Cancer Institute (NCI)-designated Atrium Health Wake Forest Baptist Comprehensive Cancer Center. Additionally, Dr. Mesa serves as the Vice Dean of the Wake Forest University School of Medicine for cancer programs and the Charles L. Spurr, MD, Professor of Internal Medicine. Dr. Mesa received his medical degree at the Mayo Clinic Alix School of Medicine in Rochester,MN where he also completed residency and fellowship training in Hematology & medical Oncology. Dr. Mesa's research focuses on MPN biology, novel therapeutics and over 100 phase I-III clinical trials, symptom assessment tools and non-pharmacological interventions to alleviate MPN symptoms and has been continuously funded by the NCI . He has led or co-led the development of 6 drugs that have been FDA-approved for MPNs. Dr. Mesa has won many career awards for his research from the Mayo Clinic, and was the 2024 Distinguished Alumnus from University of Illinois-Urbana-Champaign College of Liberal Arts and Sciences, and 2025 Recipient of the Ernest Beutler Award from American Society of Hematology.

  • Muzaffar Qazilbash, MD

    I am a Professor in the Department of Stem Cell Transplantation and Cellular Therapy at the UT MD Anderson Cancer Center, a position I have held since October 2002. My clinical and research efforts focus on enhancing outcomes for patients undergoing stem cell transplantation and cellular therapy, particularly those with multiple myeloma and related disorders. As the Director of Myeloma Transplantation and Cellular Therapy, I lead one of the largest myeloma transplant programs in the country. I have spearheaded numerous clinical trials targeting multiple myeloma and related conditions, funded by the NIH and various philanthropic organizations. With over 340 publications in peer-reviewed medical journals, I actively contribute to the scientific community and hold leadership roles in multiple institutional and extramural committees. I have had the privilege of presenting my research at major national and international symposia. Additionally, I have been deeply involved in hematology/oncology and stem cell transplantation fellowship programs for more than 20 years, playing a significant role in training the next generation of leaders in our field.

  • Dr. A. Koneti Rao

    Joshua Richter, MD, FACP

    Joshua Richter, M.D.,FACP is an Associate Professor of Medicine, Hematology and Oncology in the Myeloma Division at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai and the Director of Myeloma at the Blavatnik Family Chelsea Medical Center at Mount Sinai. He completed undergraduate work at Johns Hopkins University and subsequently went on to medical school at New York Medical College. He completed residency at St. Vincent’s Hospital – New York Medical College. Dr. Richter completed his hematology/oncology fellowship at the Yale Cancer Center. After completing fellowship he worked in the myeloma division at the John Theurer Cancer Center at Hackensack University Medical. In 2018 he joined the Myeloma Division at Mount Sinai Hospital. Dr. Richter has been published in numerous oncology journals including NEJM, Blood, and the Journal of Clinical Oncology. He has an interest in immunotherapy, multi-functional antibodies and precision medicine.

  • Saad Usmani

    Saad Usmani, MD MBA FASCO

    Dr. Usmani received his medical education at Allama Iqbal Medical College in Lahore, Pakistan. He completed a residency in internal medicine at Sinai-Grace Hospital/Wayne State University in Detroit, Michigan and a fellowship in hematology and oncology at the University of Connecticut Health Center in Farmington, Connecticut. He is the Chief of Myeloma Service at Memorial Sloan Kettering Cancer Center, and is board-certified in internal medicine, medical oncology, and hematology. He is a Fellow of the American College of Physicians, Fellow of the Royal College of Physicians (UK), and Fellow of the American Society of Clinical Oncology. He has received several international awards recognizing his clinical and translational research contributions to the field, including the Celgene Young Investigator Award for Clinical Research, COMy Award for Excellence in Myeloma Research, LLS Scholar in Clinical Research, the IMS Bart Barlogie Award for Clinical and Translational Research, the LLS CDP Achievement Award, the Giants in Cancer Care Award, and the COMy Jean-Luc Harousseau Award. He has led the clinical development of several novel therapies, has authored/co-authored more than 380 peer-reviewed research manuscripts.

  • Amer Zeidan, MBBS, MHS

    Amer Zeidan, MBBS, MHS is a Professor of Medicine at Yale School of Medicine. He serves as the Chief of the Division of Hematologic Malignancies, Director of Hematology Early Therapeutics Research, and Assistant Director of the Clinical Trial Office for Hematology at Yale Comprehensive Cancer Center (YCC). He is also the leader of Leukemia and Myeloid malignancies Clinical Research Team. Dr. Zeidan obtained his medical degree with honors from University of Jordan, followed by residency in Rochester General hospital, Rochester, NY. He then completed a Hematology/Oncology fellowship and a clinical research fellowship in myelodysplastic syndromes (MDS) at Johns Hopkins University where he also earned a Master of Health Science (MHS) degree in Clinical Investigation. He joined Yale Faculty in 2014 where he has become an internationally recognized expert in myeloid malignancies. Dr Zeidan has been conducting research on the development of novel therapies for myelodysplastic syndromes and acute myeloid leukemia (AML) with a special focus on targeted and immunotherapy-based approaches.

Speakers & Topics

Hanny Al-Samkari, MD
How I Treat Chemotherapy-Induced Thrombocytopenia
Mass General Brigham Cancer Institute, Massachusetts General Hospital, Harvard Medical School

Jennifer R. Brown, MD, PhD
Updates on Chronic Lymphocytic Leukemia
Dana-Farber Cancer Institute

Adam Cuker, MD, MS
How I Treat Refractory Immune Thrombocytopenia
Perelman School of Medicine, University of Pennsylvania

James D. Douketis, MD, FRCP(C), FCAHS
Managing Patients on Anticoagulants Who Need a Surgery/Procedure: What You Need to Know in 2026
McMaster University

Amy E. DeZern, MD, MHS
How I Manage Myelodysplastic Syndrome and Aplastic Anemia in 2026
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University

Andrew M. Evens, DO, MBA, MSc
The Treatment of Diffuse Large B-cell Lymphoma in 2026 and Beyond
Rutgers Cancer Institute of New Jersey

Brad Kahl, MD
Update in Indolent Lymphoma
Washington University in St. Louis.

Ruben A. Mesa, MD
Pivoting to Targeted MPN Therapy
Atrium Health Wake Forest Baptist Comprehensive Cancer Center

Muzaffar Qazilbash, MD
Sequencing CAR-T and Bispecific Antibodies in Myeloma
UT MD Anderson Cancer Center

Joshua Richter, MD, FACP
Myeloma…What to Do If It Relapses
The Tisch Cancer Institute, Mount Sinai

Saad Z. Usmani, MD, MBA, FASCO
Managing Smoldering and Newly Diagnosed Multiple Myeloma
Memorial Sloan Kettering Cancer Center

Amer Zeidan, MBBS, MHS
2026 Updates on Management of Acute Myeloid Leukemia
Smilow Cancer Hospital, Yale Cancer Center

In planning partnership with